Hepatitis B Virus (HBV)

Tag: HMG-CoA reductase inhibitors (Page 5)

Atorvastatin calcium: EFFICACY(5)

In a recent multicentre, randomized, parallel-group study, he comparative dose efficacy of atorvastatin at all doses was directly compared with all doses of simvastatin, pravastatin, ovastatin and fluvastatin in patients with mild to moderate hypercholesterolemia. This is the first time that the effec-:iveness of available HMG-CoA reductase inhibitors has been valuated in a single trial.

Atorvastatin calcium: EFFICACY(4)

In the lovastatin comparative study, patients were stratified by risk category for CAD, and an analysis was conducted for those patients achieving target LDL-C values within the risk groups, as established by NCEP guidelines. For patients in the low risk group (fewer than two risk factors for CAD), 6% of atorvastatin-treated patients had their dose […]

Atorvastatin calcium: EFFICACY(3)

In all three studies, results at four months showed that the starting dose of atorvastatin 10 mg/day reduced total cholesterol, LDL-C, apo B and triglyceride levels significantly more than did the starting doses of lovastatin (20 mg/day), pravastatin (20 mg/day) or simvastatin (10 mg/day). Improvements in HDL-C were comparable (Table 2). After four months of […]

Atorvastatin calcium: EFFICACY(2)

Comparative trials with other HMG-CoA reductase inhibitors The efficacy and safety of atorvastatin have been compared with those of available HMG-CoA reductase inhibitors. In three studies, atorvastatin was compared individually with lovastatin, pravastatin and simvastatin over one year in patients with mild to moderate hypercholesterolemia . These were multicentre, double-blind, randomized trials conducted in North […]

Atorvastatin calcium: EFFICACY(1)

Placebo controlled, dose-response studies In two multicentre, placebo controlled, double-blind, dose-response studies of six weeks’ duration, conducted in patients with mild to moderate hypercholesterolemia, atorvastatin 10 to 80 mg administered once-daily resulted in dose-dependent reductions of elevated levels of total cholesterol, LDL-C, triglyceride and apo B compared with placebo . HDL-C levels were modestly increased. […]

Atorvastatin calcium: PHARMACOKINETICS

the area under the plasma concentration-time curve (AUC), LDL-C reduction is similar when atorvastatin is given with and without food . Plasma atorvastatin concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration than following morning dosing . However, the reduction in LDL-C level is the same regardless of the time of […]

Atorvastatin calcium: A new HMG-CoA reductase inhibitor(4)

Atorvastatin calcium (Lipitor, Parke-Davis) is a new, synthetic, HMG-CoA reductase inhibitor approved for use in Canada and elsewhere for the treatment of dyslipidemic conditions. Its chemical structure is shown in Figure 1. Animal studies have shown that atorvastatin reduces plasma lipoprotein levels (total cholesterol, LDL-C, VLDL-C, triglyceride and apo B) to a greater extent than […]